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HSCT patients. Macrocytosis may be related to bone marrow
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This retrospective study compared the outcome following
three different conditioning regimens used for allogeneic
haematopoietic stem cell transplantation (SCT) of 445 Nordic
children with acute lymphoblastic leukemia (ALL). The chil-
dren received myeloablative conditioning with cyclophos-
phamide (n¼325), Cytarabine (Ara-C) (n¼68), Etoposide
(n¼47) or other (n¼8) in combination with total body irra-
diation (85%). The mean age at SCT was 9.0 years (0.58-
17.42), the median follow up 9.25 years (1.89-20.3). Grafts
were from sibling donors (n¼150), unrelated donors (n¼274)
or other related (n¼24). Disease status at SCT was CR1
(n¼176), CR2 (n¼204), CR3 (n¼51) or in relapse (n¼14).
Children conditioned with Etoposide and Ara-C had signiﬁ-
cantly better overall survival compared with those who
received Cyclophosphamide (pOS 0.74, 0.65 and 0.44
respectively, p<0.0001). The cumulative incidence of relapse
was 0.4 (0.35-0.46) for the Cyclophosphamide group vs 0.23
and 0.19 (p¼0.008) for the Etoposide and Ara-C group. The
cumulative incidence for non leukemia mortality was 0.17 vs
0.07 and 0.16 (p¼0.19) respectively. In a multivariate analysis
conditioning regimen was an independent prognostic factor
with the hazard ratio of 0.44 (Etoposide) and 0.56 (Ara-C),
overall p¼0.002. In conclusion we suggest that high dose
Etoposide is superior to high dose Cyclophosphamide in
conditioning for childhood ALL.253
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Background: While studies have suggested efﬁcacy of
extracorporeal photopheresis (ECP) in children with re-
fractory GVHD, few have systematically addressed the
safety proﬁle and efﬁciency of this modality. Two
frequently used instruments are UVAR-XTS and more
recently CELLEX (Therakos). Whereas UVAR-XTS is a
discontinuous ﬂow circuit designed to treat adults,
CELLEX is a near-continuous ﬂow system, decreasing
ﬂuid shifts and hypotension. In our center CELLEX is now
the modality of choice, but some patients had both during
the transition.
Methods: Retrospective chart review of patients who un-
derwent ECP with both UVAR-XTS and CELLEX in-
struments for steroid-refractory acute or chronic GVHD from
9/10-8/13 to compare treatment times, percentages of cells
treated, and complication rates (line occlusions, pre-proce-
dure blood transfusions, and major hemodynamic changes).
Mann-Whitney and Fisher’s Exact Test were used for statis-
tical analyses.
Results: Ten patients met criteria. Median age was 10.3
years (range 7.5-26.9) and weight 31.7 kg (21.8-65). A total
of 381 procedures were analyzed: 225 (59%) with UVAR-
XTS and 156 (41%) with CELLEX. Types of anti-
coagulation used included citrate and heparin. Transfusion
criteria pre-procedure were hematocrit >30% and platelet
count >50,000/ml (for patients on heparin) or > 30,000/
mL (for patients on citrate anticoagulation). Mean treat-
ment times were UVAR-XTS 190 min (65-440) and
CELLEX 117 min (50-270), p<0.0001. Average blood
volume processed with UVAR was 3.5 cycles (3-6) and
CELLEX 1118 mls (206-1626). There were 43 UVAR-XTS
and 92 CELLEX procedures with mononuclear cell (MNC)
processing data available. Mean percentage of MNCs
treated was 27% (8.6-66%) for UVAR-XTS and 34.6%
(12.1-97.7%) for CELLEX, p¼ <0.0001. With UVAR-XTS,
there were 19 (8%) procedures complicated by line oc-
clusions requiring TPA, and with CELLEX there were
4 (3%), p¼0.03. Patient-related complications included
need for pre-procedure blood transfusion and hemody-
namic changes. 32 (14%) of UVAR-XTS and 13 (8%) of
CELLEX procedures (p¼0.106) required patients to
receive blood product transfusions. 18 (8%) of UVAR-XTS
and 0 of CELLEX procedures were complicated by hy-
potension requiring ﬂuid boluses (p¼<0.0001). In 4 (2%)
UVAR-XTS and in 1 (<1%) CELLEX procedure (p¼0.653)
patients developed hypertension requiring anti-hyper-
tensive therapy.
Conclusions: This is the ﬁrst study in children comparing
efﬁciency, safety proﬁle, and percentage of cells processed
for Therakos UVAR-XTS versus CELLEX. Compared to
UVAR-XTS, CELLEX use results in shortened treatment
times, increased percentage of mononuclear cells treated per
procedure, reduced incidence of line occlusions requiring
TPA treatment, and decreased incidence of patient-related
complications, especially incidence of hypotension requiring
ﬂuid boluses.
